62 results
8-K
EX-4.1
BIVI
BioVie Inc - Ordinary Shares
4 Mar 24
BioVie Inc. Announces Proposed Public Offering of Common Stock
7:50am
, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether … be reimbursed by the other party for its attorneys’ fees and other costs and expenses incurred in the investigation, preparation and prosecution
8-K
EX-10.1
BIVI
BioVie Inc - Ordinary Shares
4 Mar 24
BioVie Inc. Announces Proposed Public Offering of Common Stock
7:50am
. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or governmental proceeding pending or, to the Company’s knowledge, threatened … notice of any investigation, proceeding or inquiry by any Governmental Entity regarding any of the matters in clauses (i) or (ii) above
8-K
EX-99.1
BIVI
BioVie Inc - Ordinary Shares
1 Mar 24
Other Events
9:40am
intrinsic and levodopa-enhancing activity of NE3107 that is consistent with data from animal models and support further clinical investigation of NE3107
8-K
EX-99.1
BIVI
BioVie Inc - Ordinary Shares
29 Nov 23
BioVie Announces EfficacyData from Phase 3 Trial of NE3107 in Patientswith Mild to Moderate Alzheimer’s Disease
8:20am
the affected sites; and
Notified the FDA’s Office of Scientific Investigation (OSI) of the potential issues at the multiple sites with GCP
8-K
EX-1.1
cy8mkln2i2
31 Aug 22
Entry into a Material Definitive Agreement
5:15pm
8-K/A
EX-10.1
p70ygdc
18 Jul 22
Entry into a Material Definitive Agreement
5:10pm
8-K
EX-10.1
ze6 5tkoqixdm
15 Jul 22
Entry into a Material Definitive Agreement
5:10pm
8-K
EX-1.1
23brrlyr btn7hc7
11 Aug 21
BioVie Inc. Announces Pricing of Public Offering of Common Stock
1:23pm